Li T, Sandberg M A, Pawlyk B S, Rosner B, Hayes K C, Dryja T P, Berson E L
Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA.
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11933-8. doi: 10.1073/pnas.95.20.11933.
A therapeutic effect of vitamin A supplementation on the course of photoreceptor degeneration, previously reported for patients with retinitis pigmentosa, was tested in two transgenic mouse models of this disease, each carrying a dominant rhodopsin mutation. The threonine-17 --> methionine (T17M) mutation is a class II rhodopsin mutation, characterized by a thermal instability/folding defect and minimal regeneration with the chromophore. The proline-347 --> serine (P347S) mutation belongs to class I, comprised of a smaller number of mutations that exhibit no recognized biochemical abnormality in vitro. In the present study, each of the two mouse models was fed a diet containing 2.5 mg of vitamin A palmitate (control) or 102.5 mg of vitamin A palmitate (high vitamin A) per kilogram of diet. Dark-adapted, full-field electroretinograms showed that the high vitamin A diet significantly reduced the rate of decline of a-wave and b-wave amplitudes in the T17M mice but had no significant effect on the decline of electroretinogram amplitude in the P347S mice. Correspondingly, histologic evaluation revealed that the treatment was associated with significantly longer photoreceptor inner and outer segments and a thicker outer nuclear layer in the T17M mice but had no effect on photoreceptor morphology in the P347S mice. In a separate series of experiments, the instability defect of the T17M mutant opsin expressed in vitro was partially alleviated by inclusion of 11-cis-retinal in the culture media. These results show that vitamin A supplementation slows the rate of photoreceptor degeneration caused by a class II rhodopsin mutation. Vitamin A supplementation may confer therapeutic benefit by stabilizing mutant opsins through increased availability of the chromophore.
先前有报道称补充维生素A对色素性视网膜炎患者的光感受器变性病程有治疗作用,本研究在两种该疾病的转基因小鼠模型中对此进行了测试,每种模型都携带显性视紫红质突变。苏氨酸-17→甲硫氨酸(T17M)突变是II类视紫红质突变,其特征是热不稳定性/折叠缺陷以及与发色团的再生极少。脯氨酸-347→丝氨酸(P347S)突变属于I类,该类突变数量较少,在体外未表现出公认的生化异常。在本研究中,给两种小鼠模型分别喂食每千克饮食中含2.5毫克棕榈酸视黄酯(对照)或102.5毫克棕榈酸视黄酯(高维生素A)的饲料。暗适应全视野视网膜电图显示,高维生素A饮食显著降低了T17M小鼠a波和b波振幅的下降速率,但对P347S小鼠视网膜电图振幅的下降没有显著影响。相应地,组织学评估显示,该治疗与T17M小鼠光感受器内节和外节显著延长以及外核层增厚有关,但对P347S小鼠的光感受器形态没有影响。在另一系列实验中,通过在培养基中加入11-顺式视黄醛,部分缓解了体外表达的T17M突变视蛋白的不稳定性缺陷。这些结果表明补充维生素A可减缓由II类视紫红质突变引起的光感受器变性速率。补充维生素A可能通过增加发色团的可用性来稳定突变视蛋白,从而带来治疗益处。